Tag: Lutathera
Novartis: result of a phase III trial with Lutathera
(CercleFinance.com) – Novartis Lutathera® significantly reduced the risk of disease progression or death by 72% as first-line treatment for patients with advanced gastroenteropancreatic neuroendocrine tumors. In the phase III NETTER-2…
Novartis: Results of a phase III trial with Lutathera
Receive the value of the day for free every morning The data collected is essential for this processing and is intended for the relevant services of BFM Bourse and, where…